Argento E, Omene E, Jaeger AH, Kertes A, Mitchell KA, Necyk C, Thielking P, Lewis EC Case report: Improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy Front Neurosci PubMed

Argento E, Shannon K, Fairbairn N, Moreheart S, Braschel M, Goldenberg S Increasing trends and incidence of nonfatal overdose among women sex workers who use drugs in British Columbia: the role of criminalization-related barriers to harm reduction Drug Alcohol Depend PubMed

Kang M, Mackay L, Christie D, Callon C, Argento E Can psychedelic-assisted psychotherapy play a role in enhancing motivation to change in addiction treatment settings? J Psychedelic Stud Link

Argento E, Socías ME, Hayashi K, Choi JC, Mackay L, Christie D, Milloy MJ, DeBeck K Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting Int J Drug Policy PubMed

Argento E, Christie D, Mackay L, Callon C, Walsh Z Psychedelic-assisted psychotherapy after COVID-19: the therapeutic uses of psilocybin and MDMA for pandemic-related mental health problems Front Psychiatry PubMed

Argento E, Tupper KW, Socías ME The tripping point: the potential role of psychedelic-assisted therapy in the response to the opioid crisis Int J Drug Policy PubMed

Argento E, Braschel M, Walsh Z, Socías ME, Shannon K The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women J Psychopharmacol PubMed

Argento E, Strathdee SA, Tupper K, Braschel M, Wood E, Shannon K Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting BMJ Open PubMed